Garden City, NY, May 03, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, today provided an update regarding its ...

Garden City, NY, Aug. 03, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next generation biotech, genomics, therapeutics and diagnostics company, today provided an update ...

Matrixx ups bid for ProPhase to $1.60 a share NEW YORK (MarketWatch) -- Matrixx Initiatives Inc. on Tuesday increased its buyout offer for ProPhase Labs Inc. by 14% to $1.60 a share in cash from its ...

ProPhase Labs, Inc. announced that CEO Ted Karkus will present at the upcoming Investor Summit Virtual on March 11, 2025, at 1:30 P.M. ET, offering investors insights into the company's operations and ...

ProPhase Labs (PRPH) and Advanced Biological Laboratories entered into a non-binding Letter of Intent regarding a proposed reverse merger transaction pursuant to which ABL would become the majority ...

ProPhase Labs is a diversified biotech company with profitable existing product lines and plans for expansion. The company's subsidiary, Nebula Genomics, offers whole genome sequencing and plans to ...

ProPhase Labs’s stock price closed at $0.44. It is down -50.000% in the last 3 months and down -94.010% in the last 12 months. ProPhase Labs saw 1 positive EPS revisions and 1 negative EPS revisions ...

Ted Karkus, Chairman & CEO, opened by emphasizing the critical importance of shareholder voting on the company's proxy, noting, "If you do not vote for our proxy, you are putting our company in harm's ...

ProPhase Labs received a 180-day extension from Nasdaq to meet its $1.00 bid price compliance requirement. ProPhase Labs Inc. announced that it has received a 180-day extension from Nasdaq to meet the ...